A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects

Summary

A randomized study of ALG-125755 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics after single doses in healthy volunteers, and single and multiple doses in CHB subjects

Timeline

Start

2022-10-07

Primary completion

2023-06-15

Completion

2023-06-15

Outcome

Outcome not reported

Stopped: “Single doses demonstrated an acceptable safety profile and antiviral activity at all doses evaluated.”

Drugs

Indications